Taking a Direct Approach: FMC-376, a Direct Inhibitor of ON+OFF KRAS G12C, Overcomes the Primary Drivers of Both Innate & Acquired Resistance

Time: 12:45 pm
day: Day One Track B AM


• Discovery of FMC-376 and demonstration of ON + OFF dual acting MOA

• Demonstration of broad activity across PDX models representing diverse clinical resistance mechanisms

• Demonstration of CNS activity and combination efficacy